相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression
Tomohiro Shibata et al.
CANCER RESEARCH (2017)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Targeting biomolecules with reversible covalent chemistry
Anupam Bandyopadhyay et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Using Protein-Confined Proximity To Determine Chemical Reactivity
Tomonori Kobayashi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Proteome-wide covalent ligand discovery in native biological systems
Keriann M. Backus et al.
NATURE (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Gizem Akcay et al.
NATURE CHEMICAL BIOLOGY (2016)
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
Kosuke Watari et al.
ONCOTARGET (2016)
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
Michael Forster et al.
CELL CHEMICAL BIOLOGY (2016)
Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution
Victor J. Cee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Eric R. Goedken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Promiscuity and Selectivity in Covalent Enzyme Inhibition: A Systematic Study of Electrophilic Fragments
Christian Joest et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis
Shyam Krishnan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Bryan R. Lannine et al.
NATURE CHEMICAL BIOLOGY (2014)
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
Phillip A. Schwartz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Benchmarking in Vitro Covalent Binding Burden As a Tool To Assess Potential Toxicity Caused by Nonspecific Covalent Binding of Covalent Drugs
Upendra P. Dahal et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Mariana Nacht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
S. Yoshikawa et al.
ONCOGENE (2013)
Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
Satoshi Sogabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Towards automated crystallographic structure refinement with phenix.refine
Pavel V. Afonine et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2012)
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Tjeerd Barf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Iminoboronates: A New Strategy for Reversible Protein Modification
Pedro M. S. D. Cal et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Iana M. Serafimova et al.
NATURE CHEMICAL BIOLOGY (2012)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Targeted covalent drugs of the kinase family
Juswinder Singh et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors
Douglas S. Johnson et al.
FUTURE MEDICINAL CHEMISTRY (2010)
Selective Covalent Labeling of Tag-Fused GPCR Proteins on Live Cell Surface with a Synthetic Probe for Their Functional Analysis
Hiroshi Nonaka et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Quantitative reactivity profiling predicts functional cysteines in proteomes
Eranthie Weerapana et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Covalent Modifiers: An Orthogonal Approach to Drug Design
Michele H. Potashman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Activity-based protein profiling: From enzyme chemistry
Benjamin F. Cravatt et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
分享论文
